Stoke Therapeutics, Inc.
stoketherapeutics.comWhat Do They Do?
Develops RNA-based medicines designed to restore protein production for people with severe genetic diseases, including Dravet syndrome and an inherited optic nerve disorder.
10-K for FY2025, filed Mar 16, 2026We are a late-stage clinical company dedicated to addressing the underlying causes of severe diseases by upregulating protein expression…View ↗
Our first investigational, new medicine in development, zorevunersen (STK-001), is a potential disease modifying medicine that is in…View ↗
Advance and expand our pipeline. We are advancing our second product candidate, STK-002, a potential disease modifying therapy for the…View ↗
We believe our ASOs can be applied to treat a wide range of severe diseases, and we have carefully designed and prioritized our pipeline…View ↗
How Do They Make Money?
$184.4M
-
10-K for FY2025, filed Mar 16, 2026
$184.4M ↗
Do Revenues Turn Into Profits?
Not on paper. It lost $6.9M in FY2025, but brought in more cash than it spent: $44.9M of free cash flow.
10-K for FY2025, filed Mar 16, 2026
−$20.6MView ↗
10-K for FY2025, filed Mar 16, 2026
−$6.9MView ↗
10-K for FY2025, filed Mar 16, 2026
$44.9MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 3, 2026
−$61.6MView ↗
- ▲ +162% (Loss)
- vs −$23.5M in Q2 FY2025
-
Mar 27, 2026
Replaced its independent accounting firm
The audit committee dismissed KPMG and engaged Ernst & Young for fiscal 2026.
Sources
8-K, filed Mar 27, 2026
On March 23, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Stoke Therapeutics, Inc. (the “Company”)…View ↗
Who Do They Compete With?
Competes with Jazz Pharmaceuticals, UCB, Ionis Pharmaceuticals, Lundbeck, Xenon Pharmaceuticals, Harmony Biosciences, Encoded Therapeutics, and PYC Therapeutics
10-K for FY2025, filed Mar 16, 2026If our current product candidate, zorevunersen, is approved for the treatment of Dravet syndrome, it may compete with other products…View ↗
Loading...
